# EDGAR Filing Document

**Accession Number:** 0001590750
**File Stem:** 0001193125-23-004046
**Filing Date:** 2023-1
**Character Count:** 42876
**Document Hash:** 3895e5be6f7eb7b1097e0a050880da4b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-004046.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001193125-23-004046

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 39

**CONFORMED PERIOD OF REPORT**: 20230108

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Viridian Therapeutics, Inc.\DE
- **CENTRAL INDEX KEY:** 0001590750
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 471187261
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36483
- **FILM NUMBER:** 23516413

**BUSINESS ADDRESS:**
- **STREET 1:** 203 CRESCENT STREET
- **STREET 2:** BLDG. 17, SUITE 102B
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** 617.272.4600

**MAIL ADDRESS:**
- **STREET 1:** 203 CRESCENT STREET
- **STREET 2:** BLDG. 17, SUITE 102B
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MIRAGEN THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20170213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MIRAGEN THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20170213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SIGNAL GENETICS, INC.
- **DATE OF NAME CHANGE:** 20140710

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 8, 2023

------

![LOGO](g427009g0108220744547.jpg)

## VIRIDIAN THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36483** | **47-1187261** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **221 Crescent Street, Suite 401**<br> **Waltham, MA** | **02453** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (617) 272-4600

#### N/A

#### (Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.01 par value | VRDN | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.**  |

---

On January 8, 2023, Viridian Therapeutics, Inc. issued a press release announcing, and made available a presentation regarding, positive topline data from its Phase 1/2 trial of VRDN-001 in patients who suffer from thyroid eye disease. The press release and data presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, which are furnished under Item 7.01 of this Current Report on Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Exhibit Description** |
| 99.1 | [Press release regarding topline data, dated January 8, 2023](d427009dex991.htm) |
| 99.2 | [Viridian Therapeutics, Inc. Topline Data Presentation, dated January 2023](d427009dex992.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Viridian Therapeutics, Inc.** | **Viridian Therapeutics, Inc.** |
| Date: January 9, 2023 | By: | /s/ Jonathan Violin |
|  |  | Jonathan Violin |
|  |  | President, Chief Executive Officer, and Director |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g427009g0108214839303.jpg)

***NEWS RELEASE***

**Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)** 

*- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results –* 

*- Among 3 mg/kg VRDN-001 treated patients, 67% were proptosis responders, 56% were overall responders, 67% achieved a Clinical Activity Score (CAS) of 0 or 1, and 20% had complete resolution of their diplopia –* 

*- Across all 21 VRDN-001 treated patients to date, 71% were proptosis responders, 67% were overall responders, 62% achieved a CAS of 0 or 1, and 54% had complete resolution of their diplopia, with a favorable safety profile seen across all dose levels –* 

*- 3 mg/kg data support planned once-monthly low-volume subcutaneous dosing profile for VRDN-002 and VRDN-003 –* 

**Waltham, Mass.** — January 8, 2023 — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline clinical data from the third, low dose cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). The Company believes this data further validate the differentiated and potentially best-in-class clinical activity of VRDN-001. The data also support the planned dosing interval for Viridian's VRDN-002 and VRDN-003 subcutaneous programs of up to once monthly.

"The rapid and meaningful improvements in signs and symptoms of TED observed with a low dose of VRDN-001 reinforce previously reported findings in this trial, and suggest that VRDN-001 may offer a differentiated efficacy profile," said Roger Turbin, M.D., Professor of Ophthalmology and Visual Science within the Department of Ophthalmology of Rutgers New Jersey Medical School, and an investigator on the VRDN-001 trial. "The data also support development of VRDN-001 as a patient-friendly low volume subcutaneous injection, which could reduce the burden of care for patients suffering from TED."

**<u>VRDN-001 – Phase 1/2 proof-of-concept trial</u>**

The proof-of-concept portion of this double-blind, placebo-controlled Phase 1/2 trial evaluated two infusions of VRDN-001 administered intravenously, three weeks apart, with efficacy measured six weeks after the first dose. VRDN-001 was evaluated at doses of 3, 10, and 20 mg/kg, with each cohort designed to include six patients randomized to drug, and two patients randomized to placebo. The Company previously announced positive results from the first two dose cohorts, which demonstrated a favorable safety profile. The third cohort evaluated a VRDN-001 dose of 3 mg/kg with 6-week data announced today. In the 3 mg/kg dose cohort, nine patients were randomized to receive VRDN-001 to enable all consented patients who were eligible following screening to participate in the trial, and two patients were randomized to receive placebo. One patient receiving placebo discontinued in the trial prior to the 6-week evaluation.

------

**<u>VRDN-001 – Safety data</u>** 

VRDN-001 was generally safe and well-tolerated by all patients treated in the three dose cohorts. There were no reported serious adverse events (SAEs), no discontinuations, and no infusion reactions in patients treated with VRDN-001 as of December 19, 2022, the most recent cut-off date for follow-up observation. The safety and tolerability profile at the 3 mg/kg dose level was generally consistent with previously reported results.

**<u>VRDN-001 – Clinical activity data</u>**

All VRDN-001 treated patients (n=21) in the 3 mg/kg (n=9), 10 mg/kg (n=6) and 20 mg/kg (n=6) cohorts were treated for two full cycles and were evaluated for changes in proptosis, clinical activity score (CAS) and diplopia. Improvement in proptosis and CAS was generally consistent across the three cohorts. A preliminary analysis of systemic IGF-1 levels, a biomarker for target engagement, shows a similar increase was also observed across the three cohorts. The following activity was observed in the 3mg/kg cohort (n=9) and across all three dose groups (n=21) at week 6:

Proptosis

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Proptosis responder rate, defined as a ≥2-millimeter (mm) reduction in proptosis from baseline as measured by exophthalmometry

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 67% in the 3mg/kg cohort

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 71% across all three dose groups

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Mean reduction in proptosis from baseline as measured by exophthalmometry

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2.7 mm in the 3mg/kg cohort

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2.3 mm across all three dose groups

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Mean reduction in proptosis from baseline as measured by blinded, centrally reviewed magnetic resonance imaging
(MRI)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2.8 mm in the 3mg/kg cohort (MRI available for 7 patients)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2.76 mm across all three dose groups (MRI available for 16 patients)

Clinical Activity Score (CAS)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Mean reduction in CAS from baseline on a 7-point measure of signs and
symptoms of TED

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 4.2-points in the 3mg/kg cohort

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 4.1-points across all three dose groups

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Maximal or near-maximal therapeutic effect on CAS, defined as reaching a CAS of 0 or 1 on the 7-point composite measure of signs and symptoms of TED

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 67% in the 3mg/kg cohort

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 62% across all three dose groups

Overall response

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Overall responder rate, defined as a ≥2 mm reduction in proptosis and a ≥2 point reduction in CAS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 56% in the 3mg/kg cohort

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 67% across all three dose groups

------

Diplopia

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Complete resolution of diplopia, defined as patients with baseline diplopia who achieved a score of 0 on the
Gorman subjective diplopia scale

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 20% in the 3mg/kg cohort (5 patients with diplopia at baseline)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 54% across all three dose groups (13 patients with diplopia at baseline)

"Data from this low dose cohort expand our overall data set to 21 drug-treated patients and build additional confidence in our ongoing Phase 3 'THRIVE' trial evaluating VRDN-001 in patients with active TED." said Barrett Katz, MD, MBA, Chief Medical Officer at Viridian. "This low dose data also increases our confidence in our planned subcutaneous program, which we are advancing as a convenient, self-administered pen."

**<u>Subcutaneous program</u>**

The Company believes that data from the 3 mg/kg dose cohort of VRDN-001 validate a low volume, subcutaneous product profile for the Company's next-generation half-life extended anti-IGF-1R antibodies VRDN-002 and VRDN-003.

VRDN-002 is a novel anti-IGF-1R monoclonal antibody that incorporates half-life extension technology. The Company previously reported that VRDN-002 demonstrated a half-life up to 43 days in healthy volunteers, supporting administration as a low-volume, subcutaneous injection up to once-monthly.

VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001, except for the addition of the half-life extension technology that is incorporated in VRDN-002.

The Company's updated pharmacokinetic (PK) modeling support feasibility of ongoing development of a self-administered pen for subcutaneous administration, and a planned dosing interval of up to once-monthly for VRDN-002 and VRDN-003.

A presentation of the VRDN-001 3 mg/kg data is available under "Events and Presentations" on the Investors section of the Viridian website at <u>viridiantherapeutics.com</u>.

**<u>Upcoming corporate priorities</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Initial VRDN-001 results from a proof-of-concept study in patients with chronic TED are expected in the first half of 2023

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• VRDN-003 IND filing with the US Food and Drug Administration is planned
for the second quarter of 2023, with Phase 1 results in healthy volunteers expected in the fourth quarter of 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• VRDN-002 results in patients with active TED are expected in the second
half of 2023

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company expects to select either the VRDN-002 or VRDN-003 subcutaneous program to advance to a pivotal Phase 3 trial in early 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Patient enrollment in the global THRIVE Phase 3 trial in patients with active TED is ongoing and results are
expected mid-2024

------

**About Viridian's Thyroid Eye Disease Pipeline (VRDN-001, -002, and -003)** 

Viridian's lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). In preclinical studies, VRDN-001 was shown to be a full antagonist of IGF-1R, with more complete receptor blockade than other anti-IGF-1R antibodies, including the only currently approved TED therapy. Data from the initial dose cohorts of the Phase 2 portion of the ongoing trial established clinical proof-of-concept for VRDN-001 in patients with active TED. Preliminary data from the ongoing trial showed treatment with VRDN-001 led to clinically meaningful reductions in proptosis, improvement in clinical activity score (CAS), and diplopia resolution. VRDN-001 was generally safe and well tolerated in the trial. The Company recently initiated its THRIVE Phase 3 trial in patients with active TED to support global marketing registration.

VRDN-001 is also being evaluated in Phase 2 trial cohorts in patients with chronic TED. Pending positive results, the Company plans to start its THRIVE-2 Phase 3 trial in patients with chronic TED.

The Company is advancing VRDN-002, a distinct anti-IGF-1R antibody incorporating half-life extension technology, and VRDN-003, a half-life extended version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous injections.

VRDN-001, -002, and -003 are investigational therapies that are not approved for any use in any country.

**About TED** 

TED is a serious and debilitating rare autoimmune disease that causes inflammation within the orbit of the eye that can cause double vision, pain, and potential blindness. TED is a progressive disease consisting of an initial active phase, followed by a transition to a secondary chronic phase. More than 50,000 and 200,000 people are estimated to suffer from active and chronic TED, respectively, in the United States and Europe.

**About Viridian Therapeutics** 

Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company recently initiated its first global Phase 3 trial called 'THRIVE' to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing two candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit <u>https://www.viridiantherapeutics.com</u>. Follow Viridian on <u>LinkedIn</u>.

------

**Note Regarding Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or other similar terms or expressions that concern the Company's expectations, plans and intentions. Forward-looking statements include, without limitation, statements regarding the Company's expectations, strategies, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations, and assumptions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: the potential efficacy and safety of VRDN-001, VRDN-002 and VRDN-003 for the treatment of TED; the relationship between the results from the positive data from the Phase 1/2 clinical trial of VRDN-001 and the results of ongoing or future clinical trials; the timing, progress and plans for the Company's ongoing and future research and clinical development programs; trial protocols for ongoing or future clinical trials, including the clinical trials for VRDN-001, VRDN-002 and VRDN-003; expectations regarding the timing for data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in the Company's clinical programs; manufacturing risks; our ability to develop a subcutaneous formulation; competition from other therapies or products; other matters that could affect the sufficiency of existing cash, cash equivalents and short-term investments to fund operations; the Company's financial position and its projected cash runway; the Company's future operating results and financial performance; the timing of pre-clinical and clinical trial activities and reporting results from same; potential addressable market size; the effects from the COVID-19 pandemic on the Company's research, development and business activities and operating results, including those risks set forth under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 11, 2022 and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

**Investor and Media Contact** 

Todd James

Viridian Therapeutics, Inc.

Senior Vice President, Corporate Affairs and Investor Relations

617-272-4691

<u>IR@viridiantherapeutics.com</u>

Source: Viridian Therapeutics, Inc.

###

## Exhibit 99.2

![Slide 1](g427009ex99_2s1g1.jpg)

VRDN-001 3 mg/kg results in patients with TED January 2023 Exhibit 99.2

------

![Slide 2](g427009ex99_2s2g1.jpg)

Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements include, without limitation, statements regarding our expectations, strategies, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: the efficacy and safety of VRDN-001, VRDN-002, and VRDN-003 for the treatment of TED; the relationship between the results from the positive data from the ongoing Phase 1/2 clinical trial of VRDN-001 and the first-in-human Phase 1 clinical trial of VRDN-002 and results or future of ongoing clinical trials; the timing, progress and plans for our ongoing or future research and clinical development programs; trial protocols for ongoing clinical trials, including the clinical trials for VRDN-001, VRDN-002, and VRDN-003; expectations regarding the timing for data, including the expected timing of additional data from the ongoing Phase 1/2 clinical trial of VRDN-001 and the first-in-human Phase 1 clinical trial of VRDN-002; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates, including VRDN-001, VRDN-002, and VRDN-003; manufacturing risks; our ability to develop a subcutaneous formulation; competition from other therapies or products; other matters that could affect the sufficiency of existing cash, cash equivalents and short-term investments to fund operations; our financial position and its projected cash runway; our future operating results and financial performance; the clinical utility of our therapeutic candidates and our intellectual property position; the timing of pre-clinical and clinical trial activities and reporting results from same; the effects from the COVID-19 pandemic on our research, development and business activities and operating results, including those risks set forth under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 11, 2022 and other subsequent disclosure documents filed with the SEC. The forward-looking statements in this presentation represent our views as of the date of this presentation. Neither we, nor our affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

------

![Slide 3](g427009ex99_2s3g1.jpg)

Viridian programs are rapidly advancing towards an estimated $4B+ TED market Key takeaways Source: Horizon Therapeutics Q3 22 earnings: peak U.S. annual net sales of >$3B and ex-U.S. estimate of >$1B peak annual net sales, includes expected entrance to Europe; Viridian-sponsored market research All data regarding third-party products in this presentation are based on third-party studies and not our own. Conclusions are not based on head-to-head clinical trial results. 1. Estimated cash, cash equivalents, and short-term investments balance as of 12/31/2022 New VRDN-001 data further support efficacy matching or exceeding Tepezza® \* at all doses with clear path to differentiation VRDN-001 has shown robust efficacy and a favorable safety profile across 21 patients with active TED; THRIVE Phase 3 is ongoing Funded to advance rapidly through multiple key milestones with $425M1 in cash & cash equivalents; runway into 2H25 VRDN-001 efficacy at 3 mg/kg supports plan for VRDN-002 or VRDN-003 as a self-administered pen with up to monthly dosing

------

![Slide 4](g427009ex99_2s4g1.jpg)

Viridian is rapidly advancing differentiated intravenous and subcutaneous anti-IGF-1R TED programs VRDN-001, -002, and -003 are investigational therapies that are not approved for any use in any country. 1) Rodon J et al, J Clin Onc, 2518 Suppl), June 2007 3) Gore L et al, Mol Cancer Ther 8(12 Suppl), 2009 2) Kurzrock R et al, Clin Cancer Res, 16(8), April, 2010 Mechanism Full antagonist Partial antagonist Partial antagonist Full antagonist Half-life ~10 to 11 days ~10 to 11 days1-3 Up to 43 days Expected to match or exceed VRDN-002 Administration Q3W IV Q3W IV Q2W or Q4W SC Q2W or Q4W SC Same extended half-life mutations Same binding domain as VRDN-001 VRDN-001 VRDN-002 VRDN-003 teprotumumab IV SC

------

![Slide 5](g427009ex99_2s5g1.jpg)

VRDN-001 proof-of-concept cohorts tested 3 doses in active TED Active TED Clinical activity score (CAS) of ≥4 Onset of symptoms within past 12 months VRDN-001 10 mg/kg Q3W x 2 (n=6) Placebo (n=2) VRDN-001 20 mg/kg Q3W x 2 (n=6) Placebo (n=2) VRDN-001 3 mg/kg Q3W x 2 (n=9) Placebo (n=1)\* \*2 patients were randomized to the placebo arm with one patient in the 3 mg/kg cohort's placebo arm discontinuing the study before week 6 10 mg/kg results: reported in August 2022, presented at ATA 2022 20 mg/kg results reported in November 2022 3 mg/kg results reported January 2023 Randomized, double-blind trial vs placebo Cohort 1 Cohort 2 Cohort 3

------

![Slide 6](g427009ex99_2s6g1.jpg)

Baseline patient characteristics similar to Tepezza trials SEM = Standard error of the mean VRDN-001 (3, 10, and 20 mg/kg) VRDN-001 3 mg/kg VRDN-001 10 mg/kg VRDN-001 20 mg/kg Placebo Tepezza Ph2 Tepezza Ph3 n 21 9 6 6 5 42 41 Proptosis, mean (SEM) 23.7 (0.7) 23.1 (1.2) 24.8 (1.2) 23.6 (1.3) 22.8 (2) 23.4 22.6 CAS, mean (SEM) 5.4 (0.2) 5.4 (0.4) 5.2 (0.3) 5.5 (0.4) 5.0 (0.5) 5.1 5.1 Diplopia, n (%) 13 (62%) 5 (56%) 4 (67%) 4 (67%) 3 (60%) 38 (90%) 28 (67%) Diplopia, mean (SEM) 1.3 (0.3) 1.3 (0.4) 1.3 (0.5) 1.3 (0.4) 1.6 (0.7) 1.8 Not reported Months since onset of TED signs/symptoms, mean (SEM) 7.4 (0.8) 7.7 (1.1) 7.3 (1.7) 6.9 (1.7) 7.0 (2.0) 4.7 6.2 Age, years (SEM) 47 (3.3) 51.2 (4.8) 38.7 (5.2) 48.8 (7.0) 44.2 (4.3) 51.6 51.6 Female, n (%) 19 (90%) 8 (89%) 4 (67%) 6 (100%) 3 (60%) 28 (65%) 29 (71%) Tepezza Phase 2 data: Smith TJ, et al, NEJM 376:18, May 2017 Tepezza Phase 3 data: Douglas RS, et al, NEJM 382:4, Jan 2020 FDA clinical review of Tepezza (BLA 761143)

------

![Slide 7](g427009ex99_2s7g1.jpg)

VRDN-001 efficacy measures compare favorably to Tepezza Clinical Activity Score (CAS) = a composite 0-7 scale scoring signs and symptoms of TED \*Diplopia was present at baseline in 13 out of 21 drug-treated patients; 4 in 10 mg/kg cohort, 4 in 20 mg/kg cohort and 5 in the 3 mg/kg cohort Overall response: Signs + symptoms (Improvement in proptosis & clinical activity score) Proptosis: Responder rate (% with ≥2mm reduction from baseline to week 6) Proptosis: Mean change by exophthalmometry (change from baseline to week 6) CAS: Score of 0 or 1 (% achieving CAS of 0 or 1 at week 6) CAS: Mean change (change from baseline to week 6) Diplopia: Complete resolution\* (% improved to a score of 0 at week 6) VRDN-001 (3, 10 or 20 mg/kg; week 6) n=21 67% 71% -2.3 mm 62% -4.1 54% 3 mg/kg / 10 mg/kg / 20 mg/kg n=9 n=6 n=6 56% 83% 67% 67% 83% 67% -2.7 mm -2.4 mm -1.7 mm 67% 83% 33% -4.2 -4.3 -3.7 20% 75% 75% Tepezza (at 10 mg/kg à 20 mg/kg; week 6) 44% 56% -1.9 mm 22% -2.1 36% Signs Improvement in proptosis Symptoms Improvement in Clinical Activity Score (CAS) and diplopia score Tepezza Phase 3 data: Douglas RS, et al, NEJM 382:4, Jan 2020, Douglas RS, et al, Ophthalmology 129:4, Apr 2022

------

![Slide 8](g427009ex99_2s8g1.jpg)

Efficacy at all doses consistent with full target engagement IGF-1 data presented as mean ± SEM \*Preliminary 3 mg/kg plasma IGF-1 levels include n=5 at week 6 and n=9 at week 3 TED IGF-1 Individual patient CAS Individual patient proptosis Measured by Hertel exophthalmometer Dose (mg/kg) Plasma IGF-1 levels (fold above baseline) Non-responders Proptosis responders Time (weeks) CAS change Dose (mg/kg) is responder threshold from baseline (change in ≥2mm) is responder threshold from baseline (change in ≥2) Change from baseline proptosis (mm) VRDN-001 20 mg/kg n=6 Placebo n=5 VRDN-001 10 mg/kg n=6 VRDN-001 3 mg/kg\* n=5

------

![Slide 9](g427009ex99_2s9g1.jpg)

Exophthalmometry and MRI together provide robust assessment of proptosis Hertel Exophthalmometer Most commonly used modality measurement of proptosis Successfully used as primary endpoint in prior clinical trials in TED Magnetic Resonance Imaging (MRI) More precise measurement Centrally read by 2 blinded reviewers Exploratory measure to potentially differentiate overall data findings Representative illustration of proptosis measurement by MRI

------

![Slide 10](g427009ex99_2s10g1.jpg)

Adj. mean proptosis change (by exophthalmometer) Mean proptosis change (by MRI) VRDN-001 responses by exophthalmometer are confirmed by centrally reviewed MRI Time (weeks) Proptosis change by MRI (from baseline to week 6) Blinded, centrally-reviewed MRI data were available for 5/5 placebo patients and 16/21 VRDN-001 patients. All MRI images were reviewed centrally by two independent, blinded readers. \*2 placebo patients and 3 VRDN-001 patients were proptosis responders by exophthalmometer, but response was not confirmed by MRI. Time (weeks) Patients where MRI did not confirm exophthalmometer response were excluded from this analysis. Placebo VRDN-001 Placebo n=5 +0.03mm VRDN-001 n=16 -2.76mm Placebo n=3 -0.3mm VRDN-001 n=18 -2.22mm Change from baseline proptosis (mm) Change from baseline proptosis (mm) Change from baseline proptosis (mm)

------

![Slide 11](g427009ex99_2s11g1.jpg)

Proptosis reduction compares favorably with Tepezza Proptosis change from baseline presented as mean ± SEM Mean proptosis change (from baseline to week 6) Proptosis responder rate at week 6 (Proptosis responder ≥2mm change from baseline proptosis) VRDN-001 Tepezza Phase 3 Tepezza Phase 2 n=42 n=41 n=21 3 mg/kg: 67% 10 mg/kg: 83% 20 mg/kg: 67% Tepezza Phase 2 data: Smith TJ, et al, NEJM 376:18, May 2017, FDA clinical review of Tepezza (BLA 761143) Tepezza Phase 3 data: Douglas RS, et al, NEJM 382:4, Jan 2020, Douglas RS, et al, Ophthalmology 129:4, Apr 2022 Measured by Hertel exophthalmometer Change from baseline proptosis (mm) 3 mg/kg: -2.7mm 10 mg/kg: -2.4mm 20 mg/kg: -1.7mm Tepezza Phase 3 Tepezza Phase 2 VRDN-001 n=42 -1.8 n=41 -1.9 n=21 -2.33

------

![Slide 12](g427009ex99_2s12g1.jpg)

Significant improvement in signs and symptoms as measured by CAS Clinical Activity Score (CAS): a composite 0-7 scale scoring signs and symptoms of TED Mean change in CAS (from baseline to week 6) Reduction in CAS (from baseline to week 6) Placebo VRDN-001 Placebo VRDN-001 n=21 n=5 3 mg/kg: 67% 10 mg/kg: 83% 20 mg/kg: 33% CAS of 0 or 1 at week 6 40% 43% 90% 76% Responders Change from baseline score Time (weeks) 3 mg/kg: -4.2 10 mg/kg: -4.3 20 mg/kg: -3.7 VRDN-001 n=21 -4.10 Placebo n=5 -1.75

------

![Slide 13](g427009ex99_2s13g1.jpg)

CAS improvement compares favorably with Tepezza Clinical Activity Score (CAS): a composite 0-7 scale scoring signs and symptoms of TED Change in Clinical Activity Score (CAS) from baseline presented as mean ± SEM Tepezza Phase 3 Tepezza Phase 2 VRDN-001 CAS of 0 or 1 at week 6 n=21 n=42 n=41 3 mg/kg: 67% 10 mg/kg: 83% 20 mg/kg: 33% VRDN-001 Tepezza Phase 3 Tepezza Phase 2 n=21 n=42 n=41 3 mg/kg: -4.2 10 mg/kg: -4.3 20 mg/kg: -3.7 Tepezza Phase 2 data: Smith TJ, et al, NEJM 376:18, May 2017 Tepezza Phase 3 data: Douglas RS, et al, NEJM 382:4, Jan 2020, FDA clinical review of Tepezza (BLA 761143) Mean CAS improvement at week 6 (Change from baseline score)

------

![Slide 14](g427009ex99_2s14g1.jpg)

S Significant improvement in both signs and symptoms of TED Overall response defined as reduction in proptosis of ≥2mm and reduction in CAS ≥2 points Tepezza Phase 2 data: FDA clinical review of Tepezza (BLA 761143) Tepezza Phase 3 data: Douglas RS, et al, NEJM 382:4, Jan 2020 VRDN-001 Tepezza Phase 3 Tepezza Phase 2 VRDN-001 Placebo Overall response at week 6 Overall response at week 6 3 mg/kg: 56% 10 mg/kg: 83% 20 mg/kg: 67% n=21 n=42 n=41 \*Excluding proptosis exophthalmometer responders that were not confirmed by MRI (where available), the overall response would be 52% for VRDN-001 and 0% for placebo 3 mg/kg: 56% 10 mg/kg: 83% 20 mg/kg: 67% n=21 n=5\*

------

![Slide 15](g427009ex99_2s15g1.jpg)

S 54% of VRDN-001 patients had complete diplopia resolution at week 6 Diplopia resolution rate defined as % of patients with diplopia at baseline that improved to a score of 0 For patients with diplopia at baseline, complete diplopia resolution defined as Gorman subjective diplopia score of zero FDA clinical review of Tepezza (BLA 761143) Placebo VRDN-001 3 mg/kg: 20% 10 mg/kg: 75% 20 mg/kg: 75% 3 mg/kg: 20% 10 mg/kg: 75% 20 mg/kg: 75% VRDN-001 Tepezza Phase 3 Tepezza Phase 2 n=13 n=38 n=28 Complete diplopia resolution at week 6 Complete diplopia resolution at week 6 n=13 n=3

------

![Slide 16](g427009ex99_2s16g1.jpg)

ADVERSE REACTIONS: VRDN-001 3 mg/kg (n=9), n VRDN-001 10 mg/kg (n=6), n VRDN-001 20 mg/kg (n=6), n Placebo (n=5), n TEPEZZA (n=84), n (%) Placebo (n=86), n (%) Muscle spasms 2 2 2\*\* - 21 (25%) 6 (7%) Nausea 2 - - - 14 (17%) 8 (9%) Alopecia - - - 1 11 (13%) 7 (8%) Diarrhea 1 2\*\* 1\* - 10 (12%) 7 (8%) Fatigue - 1 - 3 10 (12%) 6 (7%) Hyperglycemia 1 - 1\* - 8 (10%) 1 (1%) Hearing impairment 1 1 - - 8 (10%) 0 (0%) Dysgeusia - - 1 - 7 (8%) 0 (0%) Headache 2 1 1 2\*\* 7 (8%) 6 (7%) Dry skin 1 - 1 - 7 (8%) 0 (0%) Infusion reactions - - - - 4% N/A TEPEZZA label VRDN-001 3 mg/kg, 10 mg/kg, & 20 mg/kg TED cohorts No serious adverse events (SAEs), no infusion reactions, and no discontinuations in patients treated with VRDN-001 Favorable safety profile Safety profile at 3 mg/kg generally consistent with 10 and 20 mg/kg; no SAEs or infusion reactions \* Deemed unrelated to study drug by the masked investigator \*\* One patient deemed related and one patient deemed unrelated to study drug by the masked investigators Data are as of data cut-off of December 19, 2022. Other AE that occurred in more than one patient and deemed related to study drug by masked investigators was acne (n=2). Instances were mild and did not require intervention. Muscle spasms were mild and did not require intervention; hearing impairment (n=2) was "ringing in the ears" which resolved without intervention in both cases. Both patients with hyperglycemia were diabetic at baseline; in 1 case glucose variability was determined by masked PI to be unrelated to drug.

------

![Slide 17](g427009ex99_2s17g1.jpg)

Patient case report from 3 mg/kg cohort Baseline patient characteristics Proptosis: 29 mm CAS: 7 Following VRDN-001 treatment, at week 6 Change in proptosis by HE\*: -5 mm Change in proptosis by MRI: -5.2 mm Change in CAS: -6 points Case report patient information and photos taken by patient used with patient and investigator permission. \*HE = hertel exophthalmometry Photo taken by patient 2 days before first dose of VRDN-001 Photo taken by patient 2 days following second dose of VRDN-001

------

![Slide 18](g427009ex99_2s18g1.jpg)

Global Phase 3 program includes standard and accelerated treatment courses to maximize differentiation Potential improvements on Tepezza Accelerated, 12-week course of therapy Lower dose – 10mg/kg Shorter infusion times (30 min for VRDN-001 vs. 60-90 min for Tepezza) Faster onset and improved efficacy Week 24 VRDN-001, Q3W 8x VRDN-001, Q3W 5x Placebo Week 12 Primary endpoint analysis Phase 3 trial in active TED Phase 3 trial in chronic TED 4Q22 1H23 Trial Initiation

------

![Slide 19](g427009ex99_2s19g1.jpg)

Potential best-in-class subcutaneous (SC) programs in TED VRDN-001, -002, and -003 are investigational therapies that are not approved for any use in any country. 1) Rodon J et al, J Clin Onc, 2518 Suppl), June 2007 3) Gore L et al, Mol Cancer Ther 8(12 Suppl), 2009 2) Kurzrock R et al, Clin Cancer Res, 16(8), April, 2010 Mechanism Full antagonist Partial antagonist Partial antagonist Full antagonist Half-life ~10 to 11 days ~10 to 11 days1-3 up to 43 days Expected to match or exceed VRDN-002 Administration Q3W IV Q3W IV Q2W or Q4W SC Q2W or Q4W SC Plan to choose VRDN-002 or VRDN-003 for advancement as our SC program into Phase 3 trials Same extended half-life mutations Same binding domain as VRDN-001 VRDN-001 VRDN-002 VRDN-003 teprotumumab IV SC

------

![Slide 20](g427009ex99_2s20g1.jpg)

VRDN-001 data validate potential convenient, monthly low volume SC product profile for VRDN-002 and VRDN-003 PK model shows VRDN-002 and VRDN-003 dosed 2mL 300mg q2w and q4w, with a 600mg loading dose, exceed exposure of 3 mg/kg VRDN-001 IV, suggesting potential for robust efficacy via subcutaneous injection VRDN-002 half-life ~4x of VRDN-001 and teprotumumab, enabling low volume SC dosing VRDN-003 can leverage VRDN-001 exposure-response data, accelerating and de-risking path to market PK model assumes 70% bioavailability, as observed in non-human primate studies VRDN-001 IV versus VRDN-002 Q4W SC simulations VRDN-001 IV versus VRDN-003 Q4W SC simulations VRDN-001 10 mg/kg IV Q3W VRDN-001 3 mg/kg IV Q3W VRDN-002 SC Q4W 106 45 32 VRDN-001 10 mg/kg IV Q3W VRDN-001 3 mg/kg IV Q3W VRDN-003 SC Q4W 106 56 32 Cavg Cavg VRDN-002 SC Q2W 83 VRDN-003 SC Q2W 104 Drug Concentration (µg/mL) 90 60 30 0 Time (weeks) 0 10 20 30 40 Drug Concentration (µg/mL) 90 60 30 0 Time (weeks) 0 10 20 30 40

------

![Slide 21](g427009ex99_2s21g1.jpg)

VRDN-002 SC Q2W or Q4W VRDN-003 SC Q2W or Q4W Launch with self-administered pen: Selection of 1 program based on clinical data in 2H23 Phase 3 trial initiation in early 2024 Viridian plans to deliver a potential best-in-class SC therapy for patients with TED

------

![Slide 22](g427009ex99_2s22g1.jpg)

Corporate priorities VRDN-001 IV Phase 2 results in chronic TED expected in 1H23 THRIVE Phase 3 trial enrollment with topline results in active TED expected mid-2024 THRIVE-2 Phase 3 trial initiation in chronic TED planned for 1H23 THRIVE-2 Phase 3 trial topline results in chronic TED expected by YE24 VRDN-002 & VRDN-003 SC programs VRDN-002 Phase 2 results planned for 2H23 VRDN-003 IND submission to FDA planned in 2Q23 VRDN-003 Phase 1 results in healthy volunteers expected in 4Q23 Selected subcutaneous program moves into Phase 3 planned for early-2024 Continue to advance VRDN-004, -005, & -006 toward clinical development

------

![Slide 23](g427009ex99_2s23g1.jpg)

Launch potential best-in-class IV TED therapy in US and EU Rapidly follow with potential best-in-class SC TED therapy Replicate drug development and launch excellence in additional autoimmune and rare diseases Our long-term vision: building a fully-integrated biopharmaceutical company Growth Potential Value Over Time